

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Young et al  
Serial No: 10/657,363 Art Unit: 1648  
Filed: 8 September 2003 Examiner: Foley, S.  
Title: ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES  
Docket No: 469201-689

3 October 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL**

Sir:

Transmitted herewith for filing is:

1. Information Disclosure Statement;
2. Form 1449;
3. International Search Results;
4. Copies of 9 references; and
5. Self-addressed, Postage-paid Return Postcard.

No fee is believed due in making this submission. The Commissioner is authorized to charge payment of any additional filing fees required with this communication or credit any overpayment to Deposit Account No. 03-0678.


Serial No. 10/657,363  
Filed: 8 September 2003



**FIRST CLASS CERTIFICATE**

I hereby certify that this  
correspondence is being deposited  
today with the U.S. Postal Service as  
First Class Mail in an envelope  
addressed to:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


 10/3/03  
Alan J. Grant, Esq. Date

Respectfully submitted,



Alan J. Grant, Esq.  
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
Six Becker Farm Road  
Roseland, NJ 07068  
Phone: 973-994-1700  
Fax: 973-994-1744



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Young et al  
Serial No: 10/657,363 Art Unit: 1648  
Filed: 8 September 2003 Examiner: Foley, S.  
Title: ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES  
Docket No: 469201-689

3 October 2003

Commissioner for Patents  
U.S. Patent and Trademark Office  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits. No fee or statement is required.

\_\_\_\_§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

\_\_\_\_ The statement as specified in 37 CFR §1.97(e) set out below; OR

\_\_\_\_ The fee of \$240.00 under 37 CFR §1.17(p).

\_\_\_\_§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND

is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

\_\_\_\_§1.97(e) The undersigned Attorney hereby states that:

\_\_\_\_ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;  
or

\_\_\_\_ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any additional filing fees required with this communication or credit any overpayment to Deposit Account No. 03-0678.

Serial No: 10/657,363  
Filed: 8 September 2003



**FIRST CLASS CERTIFICATE**

I hereby certify that this  
correspondence is being deposited  
today with the U.S. Postal Service as  
First Class Mail in an envelope  
addressed to:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

*Alan J. Grant*

Alan J. Grant, Esq.


10/3/03  
Date

Respectfully submitted,

*Alan J. Grant*

Alan J. Grant, Esq.  
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
Six Becker Farm Road  
Roseland, NJ 07068  
Phone: 973-994-1700  
Fax: 973-994-1744

Form PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>				Atty. Docket: 469201-689		Serial No.: 10/657,363	
				Applicant: Young et al.			
				Filing Date: 8 September 2003		Group Art Unit: 1648	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1	5,929,212	27 July 1999	Jolliffe			
	B1						
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	C1	WO 99/28471	10 June 1999	PCT			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	D1	WO 00/56771	28 September 2000	PCT			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	E1	WO 00/73346	7 December 2000	PCT			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	F1	WO 96/05229	22 February 1996	PCT			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	F1	Yang et al., J. Mol. Biol. 254, 392-403 (1995)					
	G1	Egan et al, Drug Res. 49 (II), 779-790 (1999)					
	H1	Love et al, Biochemistry 32, 10950-10959 (1993)					
	I1	Whitlow et al, Protein Engineering 8, 749-761 (1995)					
	J1	Balint et al., Gene 137, 109-118 (1993)					
	K1						
	L1						
	M1						
	N1						
	O1						
	P1						
	Q1						
Examiner:					Date Considered:		
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							